Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

Circulation

Volumn 107, Issue 9, 2003, Pages 1278-1283

  Anand, Inder S ^a,f   Fisher, Lloyd D ^b   Chiang, Yann Tong ^c   Latini, Roberto ^d   Masson, Serge ^d   Maggioni, Aldo P ^e   Glazer, Robert D ^c   Tognoni, Gianni ^d   Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e ANMCO RESEARCH CENTER   (Italy)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Heart failure; Natriuretic peptides; Norepinephrine; Trials, clinical

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NORADRENALIN; VALSARTAN;

ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HEART FAILURE; HUMAN; INCIDENCE; MEASUREMENT; MORBIDITY; MORTALITY; MULTICENTER STUDY; NORADRENALIN BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; KINETICS; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PROGNOSIS; SURVIVAL ANALYSIS; TETRAZOLES; VALINE;

EID: 0037432301     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000054164.99881.00     Document Type: Article

References (23)

1. Wilson JR, Schwartz JS, St John Sutton M, et al. Prognosis in severe heart failure and relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol. 1983;2:403-409.
2. Szlachcic J, Massie BM, Kramer BL, et al. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol. 1985;55:1037-1042.
3. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
4. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
5. Massie BM, Conway M. Survival of patients with congestive heart failure: past, present, and future prospects. Circulation. 1987;7: IV11-IV19.
6. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications. A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
7. Mann D, Kent R, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
8. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
9. Anand IS, Chandrashekhar Y. Neurohormonal responses in congestive heart failure: effect of ACE inhibitors in randomized controlled clinical trials. In: Dhalla NS, Singhal PK, Beamish RE, eds. Heart Hypertrophy and Failure. Boston: Kluwer Academic Publishers; 1996:487-501.
10. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 suppl):VI40-VI48.
11. Benedict CR, Francis GS, Shelton B, et al. Effect of long-term enatapril therapy on neurohormones in patients with left ventricular dysfunction: SOLVD Investigators. Am J Cardiol. 1995;75:1151-1157.
12. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. 2002;39:1414-1421.
13. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345: 1667-1675.
14. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Val-HeFT trial. Circulation. 2002;106:2454-2458.
15. Latini R, Masson S, De Angelis N, et al. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J Cardiac Failure. 2002;8:288-299.
16. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.
17. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921-1929.
18. Bristow MR, Zelis R. Baseline and three month change in systemic venous norepinephrine as predictors of clinical outcomes in the BEST Trial investigators. J Am Coll Cardiol. 2001;37(suppl A):183A.
19. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138(6 pt 1):1126-1132.
20. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
21. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971-977.
22. Cohn J. The MOXCON study. Circulation. 1999;100:e128.
23. MERIT-HF Trial Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.